Maze Therapeutics, Inc. (MAZE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.21+1.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MAZE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress Phase 2 trials of MZE829 for APOL1-mediated kidney disease and initiate Phase 2 trials of MZE782 for PKU and CKD in 2026, with pivotal trial plans for MZE829 in 2027.
Stated as a priority in 2 of last 2 quarters. The Phase 2 HORIZON trial of MZE829 showed clinically meaningful reductions in proteinuria (35.6% mean uACR reduction in broad AMKD patients at week 12) and supports planned pivotal trial initiation in 2027. Phase 2 trials of MZE782 for PKU and CKD are on track to start in 2026 with data expected in 2027. Management is delivering on clinical development milestones consistent with stated plans.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Advancing Maze's pipeline toward late-stage clinical development and pre-commercial planning with milestones including additional data from MZE829 in late 2026 or early 2027 and trial initiations for…”
“Positive topline data from Phase 2 HORIZON trial of MZE829; Phase 2 trials of MZE782 in PKU and CKD on track to initiate in 2026 with topline data expected in 2027.”
Preserve financial resources with cash, cash equivalents, and marketable securities sufficient to fund operations through 2029 based on current business plan.
Stated as a priority in 3 of last 3 quarters. Maze reported cash, cash equivalents and marketable securities of approximately $363 million at 2026-Q1 and $360 million at 2025-Q4. Management expects these resources, including proceeds from a $150 million registered offering and a $20 million milestone payment, will fund operations into 2029. The trajectory shows maintenance of a strong cash position consistent with stated funding plans.
“Maze expects that its current cash, cash equivalents and marketable securities will fund operations into 2029 based on its current business plan.”
“Maze expects that its cash, cash equivalents and marketable securities as of March 31, 2026, together with proceeds from registered offering and milestone payment, will fund operations into 2029.”
“Maze expects that its current cash, cash equivalents and marketable securities will fund operations into 2028.”
Prepare to initiate pivotal trial for MZE829 in moderate AMKD patients without diabetes, including those with FSGS, in first half of 2027, subject to regulatory feedback.
Stated as a priority in 2 of last 2 quarters. Management plans to initiate a pivotal trial for MZE829 in moderate AMKD patients without diabetes in the first half of 2027, following positive Phase 2 data. The company is delivering on clinical development milestones aligned with this timeline.
“Looking ahead to several important milestones, including additional data from MZE829 in broad AMKD patients in late 2026 or early 2027 and advancing MZE829 into a pivotal trial.”
“Maze plans to initiate a pivotal trial in patients with moderate AMKD without diabetes, including those with FSGS, in the first half of 2027.”
Control operating expenses while advancing clinical trials, balancing increased R&D and G&A costs with financial resources.
Newly stated in 2026-Q1. Operating expenses increased with R&D rising from $27.6 million in 2025-Q1 to $34.1 million in 2026-Q1 and G&A from $7.8 million to $12.4 million, reflecting higher clinical trial and personnel costs. Management is balancing expense growth with clinical development needs.
“R&D expenses were $34.1 million and G&A expenses were $12.4 million for the quarter ended March 31, 2026, reflecting higher clinical trial and personnel costs.”
Maze aims to fund its operations into 2028 using current cash, cash equivalents, and marketable securities.
Over the trailing year it converted 0.93x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.